Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New pharmacological developments in antidepressants.

C M Pare

    Psychopathology
    |January 1, 1986
    PubMed
    Summary
    This summary is machine-generated.

    New antidepressant developments, particularly monoamine oxidase inhibitors (MAOIs), are reviewed. Combining an MAOI with amitriptyline lowers but does not eliminate the risk of dangerous blood pressure increases, similar to new reversible MAO-A inhibitors.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Attempts to attenuate the 'cheese effect'. Combined drug therapy in depressive illness.

    Journal of affective disorders·1985
    Same author

    The present status of monoamine oxidase inhibitors.

    The British journal of psychiatry : the journal of mental science·1985
    Same author

    Tranylcypromine isomers in depressed outpatients: effects on depression, monoamine oxidase inhibition and tyramine pressor response.

    Modern problems of pharmacopsychiatry·1983
    Same author

    Will amitriptyline prevent the "cheese" reaction of monoamine-oxidase inhibitors?

    Lancet (London, England)·1982
    Same author

    Is the failure of (-)deprenyl, a selective monoamine oxidase B inhibitor, to alleviate depression related to freedom from the cheese effect?

    Psychopharmacology·1981
    Same author

    Platelet uptake of 5-hydroxytryptamine and dopamine and its relationship to mood in normal subjects.

    Postgraduate medical journal·1980

    Area of Science:

    • Pharmacology
    • Neuroscience
    • Psychiatry

    Background:

    • Antidepressant medications are crucial for treating mood disorders.
    • Monoamine oxidase inhibitors (MAOIs) represent an important class of antidepressants.
    • Understanding the safety profile of MAOIs, especially regarding drug interactions, is vital.

    Purpose of the Study:

    • To review recent pharmacological advancements in antidepressants.
    • To specifically examine the role and safety of monoamine oxidase inhibitors (MAOIs).
    • To assess the risk of tyramine-induced hypertension when combining MAOIs with amitriptyline.

    Main Methods:

    • Literature review of pharmacological developments in antidepressants.
    • Analysis of studies focusing on monoamine oxidase inhibitors (MAOIs).

    Related Experiment Videos

  • Comparison of cardiovascular risks associated with combined MAOI-amitriptyline therapy versus novel reversible MAO-A inhibitors.

    • Main Results:

    • Combining a monoamine oxidase inhibitor (MAOI) with amitriptyline reduces the risk of a tyramine-induced hypertensive crisis.
    • This risk, however, is not entirely eliminated.
    • The residual risk is comparable to that observed with newer reversible MAO-A inhibitors, such as CGP 11305A.

    Conclusions:

    • While combining MAOIs with amitriptyline offers some safety benefits regarding blood pressure, caution is still warranted.
    • Newer reversible MAO-A inhibitors present a comparable safety profile for this specific adverse event.
    • Further research into the comparative safety and efficacy of different antidepressant classes is essential.